Glück Conviction Score™ ⓘ
Score-Verlauf (90 Tage)
Kursverlauf (12 Monate)
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bullisch | 10 % | 37.02 | +19.6 % vs SMA50 | |
| Kurs vs SMA200 | Bullisch | 15 % | 31.87 | +38.9 % vs SMA200 | |
| EMA20 vs EMA50 | Bullisch | 5 % | 41.19 | EMA50: 37.81 | |
| MACD-Histogramm | Bullisch | 10 % | 0.224 | Bullisch | |
| RSI(14) | Neutral | 10 % | 69.8 | Neutral (30–70) | |
| Stoch %K(14) | Bärisch | 5 % | 84.0 | Überkauft | |
| ADX(14)+DI | Bullisch | 10 % | 41.3 | +DI: 33.7 / −DI: 9.5 | |
| Z-Score(60) | Bärisch | 5 % | 1.93 | Extrem überkauft | |
| 52W-Position | Bullisch | 5 % | 96.6 % | Hoch 44.92 / Tief 26.13 | |
| Bollinger(20,2σ) | Bärisch | 5 % | 81.0 % | Upper 46.54 / Mid 40.61 / Lower 34.69 | |
| LinReg-Slope(60) | Bullisch | 10 % | +0.2295 | R²=0.84 / annualisiert +161.2 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-06-12 | Wright Christopher I | Director | Open Market Sale | -2.000 | 45,10 | -90.200,00 | -33,3% | |
| 2026-06-04 | Gaffin David Joseph | Officer, EVP, CLO, Alkermes, Inc. | Open Market Sale | -2.034 | 43,05 | -87.563,70 | -32,3% | |
| 2026-06-01 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -9.000 | 41,67 | -375.043,50 | -138,3% | |
| 2026-05-29 | Parisi Samuel Joseph | Officer, VP, Finance (Interim PAO) | Open Market Sale | -16.217 | 42,36 | -687.007,26 | -253,3% | |
| 2026-05-04 | Gaffin David Joseph | Officer, EVP, CLO, Alkermes, Inc. | Open Market Sale | -2.034 | 33,20 | -67.528,80 | -24,9% | |
| 2026-05-01 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -9.000 | 33,40 | -300.559,50 | -110,8% | |
| 2026-04-06 | Gaffin David Joseph | Officer, EVP, CLO, Alkermes, Inc. | Open Market Sale | -2.034 | 34,57 | -70.315,38 | -25,9% | |
| 2026-04-01 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -9.000 | 35,51 | -319.604,40 | -117,9% | |
| 2026-03-03 | Gaffin David Joseph | Officer, EVP, CLO, Alkermes, Inc. | Open Market Sale | -2.034 | 29,76 | -60.531,84 | -22,3% | |
| 2026-03-02 | Parisi Samuel Joseph | Officer, VP, Finance (Interim PAO) | Open Market Sale | -6.890 | 29,29 | -201.808,10 | -74,4% | |
| 2026-03-02 | Gaffin David Joseph | Officer, EVP, CLO, Alkermes, Inc. | Open Market Sale | -2.034 | 29,29 | -59.575,86 | -22,0% | |
| 2026-03-02 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -9.000 | 29,72 | -267.485,40 | -98,6% | |
| 2026-03-02 | Nichols Christian Todd | Officer, SVP, Chief Commercial Officer | Open Market Sale | -6.000 | 30,00 | -180.000,00 | -66,4% | |
| 2026-02-02 | Cooke Shane | Director | Open Market Sale | -32.113 | 34,78 | -1.116.877,29 | -411,9% | |
| 2026-02-02 | Cooke Shane | Director | Open Market Sale | -29.087 | 34,34 | -998.795,22 | -368,3% | |
| 2026-02-02 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -5.000 | 34,24 | -171.224,50 | -63,1% | |
| 2026-02-02 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -4.000 | 33,54 | -134.160,00 | -49,5% | |
| 2026-01-08 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -5.000 | 30,00 | -150.005,00 | -55,3% | |
| 2026-01-02 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -4.000 | 28,00 | -112.000,00 | -41,3% | |
| 2025-12-03 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -3.748 | 30,00 | -112.447,12 | -41,5% | |
| 2025-12-01 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -4.000 | 29,30 | -117.200,00 | -43,2% | |
| 2025-11-03 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -9.000 | 30,38 | -273.441,60 | -100,8% | |
| 2025-10-15 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -9.000 | 31,53 | -283.776,30 | -104,6% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 28.314.410 | 28.272.412 | 41.998 | 1.001.197.538 | Aufgestockt | +0,1% | |
| VANGUARD GROUP INC | 18.007.364 | 0 | 18.007.364 | 503.846.044 | Neu | +100,0% | |
| BAKER BROS. ADVISORS LP | 10.012.267 | 10.012.267 | 0 | 354.033.761 | Unverändert | 0,0% | |
| STATE STREET CORP | 9.465.286 | 9.472.858 | -7.572 | 334.692.513 | Reduziert | -0,1% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 7.427.397 | 0 | 7.427.397 | 262.632.758 | Neu | +100,0% | |
| RENAISSANCE TECHNOLOGIES LLC | 6.160.428 | 6.668.028 | -507.600 | 217.832.734 | Reduziert | -7,6% | |
| AMERICAN CENTURY COMPANIES INC | 6.072.103 | 5.956.824 | 115.279 | 214.709.656 | Aufgestockt | +1,9% | |
| DIMENSIONAL FUND ADVISORS LP | 4.522.378 | 4.412.783 | 109.595 | 159.850.354 | Aufgestockt | +2,5% | |
| Commodore Capital LP | 4.200.000 | 3.550.000 | 650.000 | 148.512.000 | Aufgestockt | +18,3% | |
| GEODE CAPITAL MANAGEMENT, LLC | 4.182.267 | 4.080.776 | 101.491 | 147.910.817 | Aufgestockt | +2,5% | |
| JPMORGAN CHASE & CO | 5.184.547 | 0 | 5.184.547 | 145.063.637 | Neu | +100,0% | |
| Deep Track Capital, LP | 3.590.323 | 2.000.000 | 1.590.323 | 126.953.821 | Aufgestockt | +79,5% | |
| WELLINGTON MANAGEMENT GROUP LLP | 2.970.166 | 3.020.442 | -50.276 | 105.025.069 | Reduziert | -1,7% | |
| FIRST TRUST ADVISORS LP | 2.968.785 | 1.454.002 | 1.514.783 | 104.976.237 | Aufgestockt | +104,2% | |
| PRIMECAP MANAGEMENT CO/CA/ | 2.539.990 | 2.564.300 | -24.310 | 89.814.046 | Reduziert | -0,9% | |
| Nuveen, LLC | 2.460.569 | 2.427.028 | 33.541 | 87.005.720 | Aufgestockt | +1,4% | |
| CITADEL ADVISORS LLC | 2.331.284 | 1.302.468 | 1.028.816 | 82.434.202 | Aufgestockt | +79,0% | |
| Holocene Advisors, LP | 2.317.326 | 0 | 2.317.326 | 81.940.647 | Neu | +100,0% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2.236.756 | 2.152.756 | 84.000 | 79.091.692 | Aufgestockt | +3,9% | |
| BVF INC/IL | 2.000.000 | 0 | 2.000.000 | 70.720.000 | Neu | +100,0% | |
| Soleus Capital Management, L.P. | 1.970.864 | 1.322.364 | 648.500 | 69.689.751 | Aufgestockt | +49,0% | |
| GOLDMAN SACHS GROUP INC | 1.882.178 | 2.267.588 | -385.410 | 66.553.814 | Reduziert | -17,0% | |
| LOOMIS SAYLES & CO L P | 1.784.581 | 1.902.522 | -117.941 | 63.102.785 | Reduziert | -6,2% | |
| MORGAN STANLEY | 1.736.091 | 1.888.487 | -152.396 | 61.388.191 | Reduziert | -8,1% | |
| NORTHERN TRUST CORP | 1.697.082 | 1.653.475 | 43.607 | 60.008.821 | Aufgestockt | +2,6% | |
| RTW INVESTMENTS, LP | 1.672.356 | 1.672.356 | 0 | 59.134.508 | Unverändert | 0,0% | |
| NORGES BANK | 1.945.734 | 0 | 1.945.734 | 54.441.637 | Neu | +100,0% | |
| Affinity Asset Advisors, LLC | 1.350.000 | 1.000.000 | 350.000 | 47.736.000 | Aufgestockt | +35,0% | |
| FMR LLC | 1.323.747 | 1.355.253 | -31.506 | 46.807.685 | Reduziert | -2,3% | |
| BANK OF AMERICA CORP /DE/ | 1.210.851 | 1.333.105 | -122.254 | 42.815.692 | Reduziert | -9,2% | |
| Avoro Capital Advisors LLC | 1.200.000 | 1.400.000 | -200.000 | 42.432.000 | Reduziert | -14,3% | |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1.450.841 | 0 | 1.450.841 | 40.594.531 | Neu | +100,0% | |
| Artisan Partners Limited Partnership | 1.111.741 | 1.349.122 | -237.381 | 39.311.162 | Reduziert | -17,6% | |
| MARSHALL WACE, LLP | 999.322 | 129.899 | 869.423 | 35.336.026 | Aufgestockt | +669,3% | |
| PRINCIPAL FINANCIAL GROUP INC | 958.016 | 947.623 | 10.393 | 33.875.444 | Aufgestockt | +1,1% | |
| PANAGORA ASSET MANAGEMENT INC | 932.942 | 928.964 | 3.978 | 32.988.829 | Aufgestockt | +0,4% | |
| Pictet Asset Management Holding SA | 942.184 | 1.477.214 | -535.030 | 30.167.161 | Reduziert | -36,2% | |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 791.963 | 796.968 | -5.005 | 28.003.812 | Reduziert | -0,6% | |
| TWO SIGMA INVESTMENTS, LP | 780.683 | 1.213.397 | -432.714 | 27.604.951 | Reduziert | -35,7% | |
| VIRGINIA RETIREMENT SYSTEMS ET Al | 976.483 | 0 | 976.483 | 27.321.994 | Neu | +100,0% | |
| AMERIPRISE FINANCIAL INC | 741.141 | 531.362 | 209.779 | 26.206.748 | Aufgestockt | +39,5% | |
| D. E. Shaw & Co., Inc. | 710.297 | 911.272 | -200.975 | 25.116.102 | Reduziert | -22,1% | |
| Frazier Life Sciences Management, L.P. | 700.647 | 700.647 | 0 | 24.774.878 | Unverändert | 0,0% | |
| PUBLIC SECTOR PENSION INVESTMENT BOARD | 677.405 | 671.170 | 6.235 | 23.953.041 | Aufgestockt | +0,9% | |
| Man Group plc | 625.046 | 312.512 | 312.534 | 22.101.626 | Aufgestockt | +100,0% | |
| Bain Capital Life Sciences Investors, LLC | 610.000 | 0 | 610.000 | 21.569.600 | Neu | +100,0% | |
| BALYASNY ASSET MANAGEMENT L.P. | 586.775 | 1.099.333 | -512.558 | 20.748.364 | Reduziert | -46,6% | |
| SEGALL BRYANT & HAMILL, LLC | 585.769 | 615.292 | -29.523 | 20.712.792 | Reduziert | -4,8% | |
| Woodline Partners LP | 558.567 | 558.567 | 0 | 19.750.929 | Unverändert | 0,0% | |
| Pacer Advisors, Inc. | 674.874 | 0 | 674.874 | 18.882.975 | Neu | +100,0% |
Top-Fondshalter (Stand: 31.03.2026) ⓘ
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) |
|---|---|---|---|---|---|
| BlackRock, Inc. | 28.314.410 | 28.272.412 | +0,1% | 1.001.197.538 | 18,17 |
| BAKER BROS. ADVISORS LP | 10.012.267 | 10.012.267 | 0,0% | 354.033.761 | 6,42 |
| STATE STREET CORP | 9.465.286 | 9.472.858 | -0,1% | 334.692.513 | 6,07 |
| VANGUARD CAPITAL MANAGEMENT LLC | 7.427.397 | 0 | +100,0% | 262.632.758 | 4,77 |
| RENAISSANCE TECHNOLOGIES LLC | 6.160.428 | 6.668.028 | -7,6% | 217.832.734 | 3,95 |
| AMERICAN CENTURY COMPANIES INC | 6.072.103 | 5.956.824 | +1,9% | 214.709.656 | 3,90 |
| DIMENSIONAL FUND ADVISORS LP | 4.522.378 | 4.412.783 | +2,5% | 159.850.354 | 2,90 |
| Commodore Capital LP | 4.200.000 | 3.550.000 | +18,3% | 148.512.000 | 2,69 |
| GEODE CAPITAL MANAGEMENT, LLC | 4.182.267 | 4.080.776 | +2,5% | 147.910.817 | 2,68 |
| Deep Track Capital, LP | 3.590.323 | 2.000.000 | +79,5% | 126.953.821 | 2,30 |
| JPMORGAN CHASE & CO | 4.101.789 | 5.184.547 | -20,9% | 123.668.951 | 2,24 |
| WELLINGTON MANAGEMENT GROUP LLP | 2.970.166 | 3.020.442 | -1,7% | 105.025.069 | 1,91 |
| FIRST TRUST ADVISORS LP | 2.968.785 | 1.454.002 | +104,2% | 104.976.237 | 1,90 |
| PRIMECAP MANAGEMENT CO/CA/ | 2.539.990 | 2.564.300 | -0,9% | 89.814.046 | 1,63 |
| Nuveen, LLC | 2.460.569 | 2.427.028 | +1,4% | 87.005.720 | 1,58 |
| CITADEL ADVISORS LLC | 2.331.284 | 1.302.468 | +79,0% | 82.434.202 | 1,50 |
| Holocene Advisors, LP | 2.317.326 | 0 | +100,0% | 81.940.647 | 1,49 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2.236.756 | 2.152.756 | +3,9% | 79.091.692 | 1,44 |
| BVF INC/IL | 2.000.000 | 0 | +100,0% | 70.720.000 | 1,28 |
| Soleus Capital Management, L.P. | 1.970.864 | 1.322.364 | +49,0% | 69.689.751 | 1,26 |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 31.03.2026 | ✓ | 385 | 184,2 | 6.214 |
| 31.12.2025 | ✓ | 365 | 186,1 | 4.886 |
| 30.09.2025 | ✓ | 359 | 176,9 | 4.914 |
| 30.06.2025 | ✓ | 354 | 170,9 | 4.475 |
| 31.03.2025 | ✓ | 367 | 179,3 | 5.308 |
| 31.12.2024 | ✓ | 337 | 171,1 | 4.361 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) ⓘ |
|---|---|---|
| Deep Track Capital, LP | 2.000.000 | 55.960.000 |
| NORGES BANK | 1.945.734 | 54.441.637 |
| Soleus Capital Management, L.P. | 1.322.364 | 36.999.745 |
| BALYASNY ASSET MANAGEMENT L.P. | 1.099.333 | 30.759.337 |
| Opaleye Management Inc. | 490.000 | 13.710.200 |
| GLENMEDE TRUST CO NA | 412.920 | 11.553.500 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 361.387 | 10.112.000 |
| Bridgewater Associates, LP | 344.452 | 9.637.767 |
| Qube Research & Technologies Ltd | 276.558 | 7.738.093 |
| Abacus FCF Advisors LLC | 219.495 | 6.141.470 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| WELLINGTON MANAGEMENT GROUP LLP | 3.020.442 | 2.645.252 | +705.0 % | 84.511.968 |
| BAKER BROS. ADVISORS LP | 10.012.267 | 1.920.916 | +23.7 % | 280.143.231 |
| UBS Group AG | 2.544.895 | 1.790.729 | +237.4 % | 71.206.162 |
| AMERICAN CENTURY COMPANIES INC | 5.956.824 | 1.559.353 | +35.5 % | 166.671.997 |
| JPMORGAN CHASE & CO | 5.184.547 | 1.256.377 | +32.0 % | 145.063.637 |
| STATE STREET CORP | 9.472.858 | 932.507 | +10.9 % | 265.050.567 |
| DIMENSIONAL FUND ADVISORS LP | 4.412.783 | 714.787 | +19.3 % | 123.466.744 |
| Squarepoint Ops LLC | 1.095.846 | 650.540 | +146.1 % | 30.661.771 |
| Pictet Asset Management Holding SA | 1.477.214 | 584.168 | +65.4 % | 41.343.880 |
| TWO SIGMA INVESTMENTS, LP | 1.213.397 | 556.898 | +84.8 % | 33.950.848 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| PRICE T ROWE ASSOCIATES INC /MD/ | 8.998.963 | -1.239.394 | -12.1 % | 251.792 |
| Avoro Capital Advisors LLC | 1.400.000 | -840.000 | -37.5 % | 39.172.000 |
| Artisan Partners Limited Partnership | 1.349.122 | -760.650 | -36.1 % | 37.748.434 |
| Man Group plc | 312.512 | -584.762 | -65.2 % | 8.744.086 |
| Sio Capital Management, LLC | 95.353 | -579.487 | -85.9 % | 2.667.977 |
| JANE STREET GROUP, LLC | 104.270 | -448.511 | -81.1 % | 2.917.475 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 279.573 | -405.438 | -59.2 % | 7.822.453 |
| MACKENZIE FINANCIAL CORP | 95.447 | -346.903 | -78.4 % | 2.649.159 |
| BNP PARIBAS FINANCIAL MARKETS | 430.330 | -330.873 | -43.5 % | 12.040.633 |
| Handelsbanken Fonder AB | 55.000 | -277.100 | -83.4 % | 1.539 |
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Zweck |
|---|---|---|---|---|---|---|
| 15.05.2026 | T. Rowe Price Associates, Inc. | Passiv (13G/A) | 2,80 % | 4.664.563 | -3,30 pp | |
| 28.04.2026 | Vanguard Portfolio Management | Passiv (13G) | 5,80 % | 9.647.056 | Neu | |
| 28.04.2026 | Vanguard Capital Management | Passiv (13G) | 5,21 % | 8.676.888 | Neu | |
| 26.03.2026 | The Vanguard Group | Passiv (13G/A) | Ausstieg | 0 | -11,52 pp | |
| 17.02.2026 | Baker Bros. Advisors LP | Passiv (13G) | 6,10 % | 10.012.267 | Neu | |
| 17.02.2026 | Baker Bros. Advisors (GP) LLC | Passiv (13G) | 6,10 % | 10.012.267 | Neu | |
| 17.02.2026 | Julian C. Baker | Passiv (13G) | 6,10 % | 10.012.267 | Neu | |
| 17.02.2026 | Felix J. Baker | Passiv (13G) | 6,10 % | 10.012.267 | Neu | |
| 10.11.2025 | STATE STREET CORPORATION | Passiv (13G) | 5,20 % | 8.540.351 | +0,30 pp | |
| 14.08.2025 | T. Rowe Price Associates, Inc. | Passiv (13G/A) | 6,10 % | 10.041.900 | Neu | |
| 13.05.2025 | STATE STREET CORPORATION | Passiv (13G) | 4,90 % | 8.022.670 | Neu | |
| 28.04.2025 | BlackRock, Inc. | Passiv (13G/A) | 15,80 % | 25.638.477 | Neu | |
| 10.02.2025 | Wellington Investment Advisors Holdings LLP | Passiv (13G/A) | 4,30 % | 7.012.483 | -3,39 pp | |
| 10.02.2025 | Wellington Management Group LLP | Passiv (13G/A) | 4,30 % | 7.012.483 | -3,39 pp | |
| 10.02.2025 | Wellington Group Holdings LLP | Passiv (13G/A) | 4,30 % | 7.012.483 | -3,39 pp | |
| 14.11.2024 | T. ROWE PRICE ASSOCIATES, INC. | Passiv (13G) | 7,90 % | 12.998.606 | +7,00 pp | |
| 12.11.2024 | The Vanguard Group | Passiv (13G/A) | 11,52 % | 18.971.637 | 0,00 pp | |
| 08.11.2024 | Wellington Investment Advisors Holdings LLP | Passiv (13G/A) | 7,69 % | 12.658.245 | -1,44 pp | |
| 08.11.2024 | Wellington Group Holdings LLP | Passiv (13G/A) | 7,69 % | 12.658.245 | -1,44 pp | |
| 08.11.2024 | Wellington Management Company LLP | Passiv (13G/A) | 7,61 % | 12.539.143 | -1,35 pp | |
| 08.11.2024 | Wellington Management Group LLP | Passiv (13G/A) | 7,69 % | 12.658.245 | -1,44 pp | |
| 04.11.2024 | The Vanguard Group | Passiv (13G) | 11,52 % | 18.971.637 | -1,04 pp | |
| 13.02.2024 | The Vanguard Group | Passiv (13G/A) | 12,56 % | 20.955.454 | +1,28 pp | |
| 08.02.2024 | Wellington Group Holdings LLP | Passiv (13G) | 9,13 % | 15.241.470 | +5,45 pp | |
| 08.02.2024 | Wellington Investment Advisors Holdings LLP | Passiv (13G) | 9,13 % | 15.241.470 | +5,45 pp | |
| 08.02.2024 | Wellington Management Company LLP | Passiv (13G) | 8,96 % | 14.948.347 | +1,64 pp | |
| 08.02.2024 | Wellington Management Group LLP | Passiv (13G) | 9,13 % | 15.241.470 | +5,45 pp | |
| 24.01.2024 | : STATE STREET CORPORATION | Passiv (13G) | 5,60 % | 0 | Neu | |
| 24.08.2023 | Alexander J. Denner, Ph.D. | Aktivist (13D/A) | 5,00 % | 8.323.400 | -3,45 pp | |
| 24.08.2023 | Sarissa Capital Management LP | Aktivist (13D/A) | 5,00 % | 8.323.400 | -3,45 pp | |
| 05.06.2023 | Alexander J. Denner, Ph.D. | Aktivist (13D/A) | 8,45 % | 14.040.000 | -0,09 pp | |
| 05.06.2023 | Sarissa Capital Management LP | Aktivist (13D/A) | 8,45 % | 14.040.000 | -0,09 pp | |
| 14.02.2023 | T. ROWE PRICE ASSOCIATES, INC. | Passiv (13G/A) | 0,90 % | 1.570.313 | -7,00 pp | |
| 09.02.2023 | The Vanguard Group | Passiv (13G/A) | 11,28 % | 18.539.078 | +0,83 pp | |
| 06.02.2023 | Sarissa Capital Management LP | Aktivist (13D/A) | 8,54 % | 14.040.000 | -0,01 pp | |
| 06.02.2023 | Alexander J. Denner, Ph.D. | Aktivist (13D/A) | 8,54 % | 14.040.000 | -0,01 pp | |
| 06.02.2023 | Wellington Investment Advisors Holdings LLP | Passiv (13G/A) | 3,68 % | 6.044.378 | -3,64 pp | |
| 06.02.2023 | Wellington Group Holdings LLP | Passiv (13G/A) | 3,68 % | 6.044.378 | -3,64 pp | |
| 06.02.2023 | Wellington Management Group LLP | Passiv (13G/A) | 3,68 % | 6.044.378 | -3,64 pp | |
| 07.10.2022 | Alexander J. Denner, Ph.D. | Aktivist (13D/A) | 8,55 % | 14.040.000 | 0,00 pp |
Stammdaten
Alkermes plc ist ein biopharmazeutisches Unternehmen, das Arzneimittel erforscht, entwickelt und vermarktet, um ungedeckte medizinische Bedürfnisse von Patienten in verschiedenen therapeutischen Bereichen in den Vereinigten Staaten, Irland und international zu erfüllen. Zu seinen Produkten auf dem Markt gehören ARISTADA, eine intramuskuläre Injektionssuspension zur Behandlung von Schizophrenie; VIVITROL zur Behandlung von Alkohol und Prävention von Opioidabhängigkeit; RISPERDAL CONSTA zur Behandlung von Schizophrenie und bipolarer Störung I; INVEGA SUSTENNA zur Behandlung von Schizophrenie und schizoaffektiver Störung; XEPLION, INVEGA TRINZA und TREVICTA zur Behandlung von Schizophrenie und schizoaffektiver Störung; und VUMERITY zur Behandlung rückfallender Formen von Multipler Sklerose bei Erwachsenen, einschließlich klinisch isoliertem Syndrom, schubförmig remittierender und aktiver sekundär progredienter Erkrankung. Das Unternehmen entwickelt auch LYBALVI, einen oralen atypischen Antipsychotikakandidat zur Behandlung von Erwachsenen mit Schizophrenie und bipolarer Störung I; und nemvaleukin alfa, ein entwickeltes Fusionsprotein zur Erweiterung von tumorbekämpfenden Immunzellen und zur Vermeidung der Aktivierung immunsuppressiver Zellen. Es hat Kooperationsvereinbarungen hauptsächlich mit Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc und Janssen Pharmaceutica International. Alkermes plc wurde 1987 gegründet und hat seinen Sitz in Dublin, Irland.
Unternehmen & Branche
| Name | Alkermes plc. |
|---|---|
| Ticker | ALKS |
| CIK | 0001520262 |
| Boerse | Nasdaq |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | G01767105 |
|---|---|
| ISIN | USG017671052 |
| Typ | Common Stock |
| Marktkapitalisierung | 7,55 Mrd. USD |
| KGV (P/E) | 31,89 |
| Beta | 0,27 |
Bewertung
| KBV (P/B) | 4,15 vs. 3,39 (2021) ▲ |
|---|---|
| KUV (P/S) | 5,12 vs. 3,21 (2021) ▲ |
| EV/EBITDA | 25,7 vs. 21,8 (2021) ▲ |
| FCF-Rendite | 6,4 % vs. 2,0 % (2021) ▲ |
Qualität & Bilanz
| Bruttomarge | 86,7 % vs. 83,2 % (2021) ▲ |
|---|---|
| Operative Marge | 17,2 % vs. 8,3 % (2021) ▲ |
| Nettomarge | 16,4 % vs. -4,1 % (2021) ▲ |
| ROIC | 12,8 % vs. -3,2 % (2021) ▲ |
| Nettoverschuldung/EBITDA | -1,1 vs. 0,4 (2021) ▼ |
| Zinsdeckungsgrad | 20,7 vs. 8,7 (2021) ▲ |
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2021. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2021 | 2022 | 2023 | 2024 | 2025 | Verlauf |
|---|---|---|---|---|---|---|
| Bewertung | ||||||
| KBV (P/B) | 3,39 | 4,12 | 3,85 | 3,18 | 2,55 | |
| KUV (P/S) | 3,21 | 3,86 | 2,78 | 2,99 | 3,14 | |
| EV/EBITDA | 21,8 | 61,1 | 9,3 | 9,9 | 15,3 | |
| FCF-Rendite | 2,0 % | -0,4 % | 7,6 % | 8,7 % | 10,4 % | |
| Qualität & Bilanz | ||||||
| Bruttomarge | 83,2 % | 80,4 % | 84,8 % | 84,2 % | 86,7 % | |
| Operative Marge | 8,3 % | -0,5 % | 24,9 % | 27,0 % | 17,2 % | |
| Nettomarge | -4,1 % | -14,2 % | 21,4 % | 23,6 % | 16,4 % | |
| ROIC | -3,2 % | -11,1 % | 22,6 % | 23,8 % | 12,8 % | |
| Nettoverschuldung/EBITDA | 0,4 | 1,2 | -0,2 | -0,5 | -1,1 | |
| Zinsdeckungsgrad | 8,7 | -0,5 | 18,0 | 18,6 | 20,7 | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Finanzkennzahlen (SEC XBRL) ⓘ
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | 392.911.000 | -66.480.000 | -0,40 | 4.258.076.000 | 1.751.531.000 |
| 2025-12-31 | 10-K | 1.475.899.000 | 241.664.000 | 1,43 | 2.486.993.000 | 1.819.295.000 |
| 2025-09-30 | 10-Q | 394.185.000 | 82.761.000 | 0,49 | 2.329.512.000 | 1.733.432.000 |
| 2025-06-30 | 10-Q | 390.657.000 | 87.098.000 | 0,52 | 2.252.809.000 | 1.624.584.000 |
| 2025-03-31 | 10-Q | 306.510.000 | 22.464.000 | 0,13 | 2.081.977.000 | 1.511.583.000 |
| 2024-12-31 | 10-K | 1.557.632.000 | 367.070.000 | 2,17 | 2.055.567.000 | 1.464.977.000 |
| 2024-09-30 | 10-Q | 378.143.000 | 92.381.000 | 0,55 | 2.155.291.000 | 1.292.106.000 |
| 2024-06-30 | 10-Q | 399.131.000 | 91.358.000 | 0,53 | 2.206.842.000 | 1.284.005.000 |
| 2024-03-31 | 10-Q | 350.372.000 | 36.828.000 | 0,21 | 2.123.896.000 | 1.254.763.000 |
| 2023-12-31 | 10-K | 1.663.405.000 | 355.757.000 | 2,10 | 2.136.223.000 | 1.202.686.000 |
| 2023-09-30 | 10-Q | 380.938.000 | 47.758.000 | 0,28 | 2.279.231.000 | 1.355.583.000 |
| 2023-06-30 | 10-Q | 617.397.000 | 237.065.000 | 1,38 | 2.187.184.000 | 1.280.437.000 |
| 2023-03-31 | 10-Q | 287.595.000 | -41.845.000 | -0,25 | 1.922.727.000 | 1.005.576.000 |
| 2022-12-31 | 10-K | 1.111.795.000 | -158.267.000 | -0,97 | 1.963.978.000 | 1.043.753.000 |
| 2022-10-31 | 10-K | 16.500.000 | ||||
| 2022-09-30 | 10-Q | 252.357.000 | -63.974.000 | -0,39 | 1.941.899.000 | 1.042.854.000 |
| 2022-06-30 | 10-Q | 276.219.000 | -30.136.000 | -0,18 | 1.957.417.000 | 1.082.324.000 |
| 2022-03-31 | 10-Q | 278.545.000 | -35.903.000 | -0,22 | 1.977.845.000 | 1.075.390.000 |
| 2021-12-31 | 10-K | 1.173.751.000 | -48.169.000 | -0,29 | 2.024.484.000 | 1.112.584.000 |
| 2021-09-30 | 10-Q | 294.141.000 | -28.988.000 | -0,18 | 1.995.432.000 | 1.096.168.000 |
Umsatz nach Segmenten & Regionen ⓘ
Geschäftssegmente
| Segment | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| Product | 1,2 Mrd. | 1,1 Mrd. | 920,0 Mio. | 777,6 Mio. | 627,4 Mio. | 40,1 % | +9,3% | |
| Vivitrol | 467,9 Mio. | 457,3 Mio. | 400,4 Mio. | 379,5 Mio. | 343,9 Mio. | 15,9 % | +2,3% | |
| Aristada And Aristada Initio | 370,0 Mio. | 346,2 Mio. | 327,7 Mio. | 302,1 Mio. | 275,4 Mio. | 12,5 % | +6,9% | |
| LYBALVI | 346,7 Mio. | 280,0 Mio. | 191,9 Mio. | 96,0 Mio. | 8,2 Mio. | 11,7 % | +23,8% | |
| Manufactured Product And Royalty | 291,3 Mio. | 474,1 Mio. | 743,4 Mio. | 332,0 Mio. | 541,8 Mio. | 9,9 % | -38,6% | |
| Royalty | 245,3 Mio. | 354,7 Mio. | 600,9 Mio. | 219,6 Mio. | 436,2 Mio. | 8,3 % | -30,8% | |
| Manufacturing Revenue | 46,0 Mio. | 119,4 Mio. | 142,5 Mio. | 112,4 Mio. | 105,6 Mio. | 1,6 % | -61,5% | |
| Research And Development | – | 3.000 | 19.000 | 260.000 | 1,0 Mio. | – | – | |
| License | – | – | – | 2,0 Mio. | 3,5 Mio. | – | – |
Regionen
| Region | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| US | 1,4 Mrd. | 1,4 Mrd. | 1,5 Mrd. | 932,0 Mio. | 984,2 Mio. | 93,0 % | -2,7% | |
| Foreign Country Excluding Specified Country | 102,4 Mio. | 146,2 Mio. | 170,3 Mio. | 178,0 Mio. | 187,3 Mio. | 6,9 % | -30,0% | |
| IE | 754.000 | 1,3 Mio. | 1,2 Mio. | 1,8 Mio. | 2,2 Mio. | 0,1 % | -41,7% |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q1 2026 | 31.03.2026 | 05.05.2026 | 392,9 Mio. USD | -0,40 |
| Q3 2025 | 30.09.2025 | 28.10.2025 | 394,2 Mio. USD | 0,49 |
| Q2 2025 | 30.06.2025 | 28.10.2025 | 390,7 Mio. USD | 0,52 |
| Q1 2025 | 31.03.2025 | 05.05.2026 | 306,5 Mio. USD | 0,13 |
| Q3 2024 | 30.09.2024 | 28.10.2025 | 378,1 Mio. USD | 0,55 |
| Q2 2024 | 30.06.2024 | 28.10.2025 | 399,1 Mio. USD | 0,53 |
| Q1 2024 | 31.03.2024 | 28.10.2025 | 350,4 Mio. USD | 0,21 |
| Q3 2023 | 30.09.2023 | 24.10.2024 | 380,9 Mio. USD | 0,28 |
| Q2 2023 | 30.06.2023 | 24.10.2024 | 617,4 Mio. USD | 1,38 |
Einreichungs-Historie (10-K / 10-Q)
SEC-Einreichungs-Historie der Quartalsberichte (10-Q) und Jahresberichte
(10-K) der letzten sechs Jahre. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 05.05.2026 | 10-Q | 31.03.2026 | 35 Tage | SEC » |
| 25.02.2026 | 10-K | 31.12.2025 | 56 Tage | SEC » |
| 28.10.2025 | 10-Q | 30.09.2025 | 28 Tage | SEC » |
| 29.07.2025 | 10-Q | 30.06.2025 | 29 Tage | SEC » |
| 01.05.2025 | 10-Q | 31.03.2025 | 31 Tage | SEC » |
| 12.02.2025 | 10-K | 31.12.2024 | 43 Tage | SEC » |
| 24.10.2024 | 10-Q | 30.09.2024 | 24 Tage | SEC » |
| 24.07.2024 | 10-Q | 30.06.2024 | 24 Tage | SEC » |
| 01.05.2024 | 10-Q | 31.03.2024 | 31 Tage | SEC » |
| 21.02.2024 | 10-K | 31.12.2023 | 52 Tage | SEC » |
| 25.10.2023 | 10-Q | 30.09.2023 | 25 Tage | SEC » |
| 26.07.2023 | 10-Q | 30.06.2023 | 26 Tage | SEC » |
| 26.04.2023 | 10-K/A | 31.12.2022 | 116 Tage | SEC » |
| 26.04.2023 | 10-Q | 31.03.2023 | 26 Tage | SEC » |
| 16.02.2023 | 10-K | 31.12.2022 | 47 Tage | SEC » |
| 02.11.2022 | 10-Q | 30.09.2022 | 33 Tage | SEC » |
| 27.07.2022 | 10-Q | 30.06.2022 | 27 Tage | SEC » |
| 29.04.2022 | 10-K/A | 31.12.2021 | 119 Tage | SEC » |
| 27.04.2022 | 10-Q | 31.03.2022 | 27 Tage | SEC » |
| 16.02.2022 | 10-K | 31.12.2021 | 47 Tage | SEC » |
| 27.10.2021 | 10-Q | 30.09.2021 | 27 Tage | SEC » |
| 28.07.2021 | 10-Q | 30.06.2021 | 28 Tage | SEC » |
| 29.04.2021 | 10-K/A | 31.12.2020 | 119 Tage | SEC » |
| 28.04.2021 | 10-Q | 31.03.2021 | 28 Tage | SEC » |
| 11.02.2021 | 10-K | 31.12.2020 | 42 Tage | SEC » |
| 29.10.2020 | 10-Q | 30.09.2020 | 29 Tage | SEC » |
| 29.07.2020 | 10-Q | 30.06.2020 | 29 Tage | SEC » |
Kritische 8-K Meldungen ⓘ
HOCH Abgang Schlüsselpersonen (20.05.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 20.05.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 25.02.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | e Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of… |
| 12.09.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of… |
| 21.05.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of… |
| 31.05.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of… |
| 07.03.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of… |
| 05.02.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | . ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain… |
| 08.12.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain… |
| 06.07.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | e Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of… |
| 07.07.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 14.06.2021 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 06.01.2021 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02(c) above relating to modifications to Mr. Brown’s base salary is incorporated by reference in this Item… |
| 20.05.2020 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
Fail-to-Deliver (6 Monate) ⓘ
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-05-07 | 3.757 | 35,32 | 132.697 |
| 2026-05-05 | 182.241 | 34,17 | 6.227.175 |
| 2026-04-24 | 1.032 | 33,91 | 34.995 |
| 2026-04-20 | 69.054 | 34,53 | 2.384.435 |
| 2026-04-08 | 46.394 | 33,02 | 1.531.930 |
| 2026-04-07 | 13 | 34,08 | 443 |
| 2026-04-01 | 19.192 | 35,36 | 678.629 |
| 2026-03-31 | 34.000 | 30,15 | 1.025.100 |
| 2026-03-23 | 29 | 28,15 | 816 |
| 2026-03-11 | 11 | 27,74 | 305 |
| 2026-03-02 | 3.839 | 30,10 | 115.554 |
| 2026-02-27 | 9.641 | 30,73 | 296.268 |
| 2026-02-13 | 67 | 33,29 | 2.230 |
| 2026-02-09 | 953 | 34,91 | 33.269 |
| 2026-01-27 | 46.390 | 33,11 | 1.535.973 |
| 2026-01-23 | 10.036 | 33,95 | 340.722 |
| 2025-12-31 | 4 | 27,81 | 111 |
| 2025-12-30 | 69 | 28,01 | 1.933 |
| 2025-12-29 | 205 | 28,49 | 5.840 |
| 2025-12-22 | 1.160 | 28,45 | 33.002 |
| 2025-12-16 | 200 | 28,17 | 5.634 |
Hinweis
Ersteller: Verantwortlich für Erstellung und Verbreitung ist der Betreiber dieser Website (siehe Impressum). Die Einstufung wird arbeitstäglich automatisiert neu berechnet — Stand: 14.06.2026.
Interessenkonflikte: Der Betreiber kann über verlinkte Anbieter (z. B. Broker) Affiliate-Vergütungen erhalten und ggf. eigene Positionen in besprochenen Werten halten. Methodik: Signal-Komponenten und Gewichte.